CompletedPhase 2NCT01679119
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University College, London
- Principal Investigator
- Andrew McMillanNottingham University Hospitals NHS Trust
- Intervention
- Cyclophosphamide(drug)
- Enrollment
- 129 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2022
Study locations (30)
- Stoke Mandeville Hospital (including Wycombe Hospital), Aylesbury, United Kingdom
- North Hampshire Hospital, Basingstoke, United Kingdom
- Royal United Hospital, Bath, United Kingdom
- Royal Bournemouth Hospital, Bournemouth, United Kingdom
- Bristol Oncology Centre, Bristol, United Kingdom
- West Suffolk Hospital, Bury St Edmunds, United Kingdom
- Kent and Canterbury Hospital, Canterbury, United Kingdom
- Castle Hill Hospital, Cottingham, United Kingdom
- University Hospital, Coventry, Coventry, United Kingdom
- Darent Valley Hospital, Dartford, United Kingdom
- Royal Devon & Exeter Hospital, Exeter, United Kingdom
- Medway Maritime Hospital, Gillingham, United Kingdom
- Beatson West of Scotland Cancer Centre (including Gartnavel Royal Hospital), Glasgow, United Kingdom
- James Paget University Hospital, Great Yarmouth, United Kingdom
- Northwick Park Hospital, Harrow, United Kingdom
- +15 more locations on ClinicalTrials.gov
Collaborators
Pfizer · Cancer Research UK
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01679119 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.